Genetic Signatures

Genetic Signatures Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Genetic Signatures (GSS.AX) as of Nov 5, 2026 is 66.00. In the previous year, Cash Conversion Cycle (CCC) was 359.01 — a change of -81.62% (lower).

Cash Conversion Cycle

66.00

YoY

-81.62%

Last updated:

Cash Conversion Cycle (CCC) of Genetic Signatures is 2026 66.00 . Cash Conversion Cycle (CCC) of Genetic Signatures was 2025 359.01 . It decreases by -81.62% lower compared to the previous year.

The Genetic Signatures Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
145.44 AUD
Jan 1, 2020
297.24 AUD
Jan 1, 2021
208.45 AUD
Jan 1, 2022
127.98 AUD
Jan 1, 2023
130.11 AUD
Jan 1, 2024
365.89 AUD
Jan 1, 2025
359.01 AUD
Jan 1, 2026
66.00 AUD
The Genetic Signatures Cash Conversion Cycle history
YEARCash Conversion CycleYoY
66.00-81.62%
359.01-1.88%
365.89+181.22%
130.11+1.66%
127.98-38.60%
208.45-29.87%
297.24+104.37%
145.44-16.10%
173.36+146.11%
70.44-40.98%
119.36+38.74%
86.03-566.64%
-18.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Cash Conversion Cycle (CCC) of Genetic Signatures is 66.00 in 2026.

Cash Conversion Cycle (CCC) of Genetic Signatures changed from 359.01 to 66.00, representing a -81.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genetic Signatures

All Key Metrics — Genetic Signatures